内分泌治療薬市場：治療領域、薬剤クラス別、投与方法、患者年齢層、流通チャネル別-2025-2030年の世界予測

内分泌治療薬市場の2023年の市場規模は571億1,000万米ドルで、2024年にはCAGR 7.34%で610億6,000万米ドルに成長し、2030年には938億米ドルに達すると予測されています。

内分泌医薬品は、研究の進歩とホルモンバランスの乱れや代謝異常に対する理解の深まりによって、現代ヘルスケアにおける必需品として、またダイナミックな展望として台頭してきました。この包括的な概要では、新たな動向、市場セグメンテーションの詳細、戦略的な地域シフトを明らかにしながら、内分泌市場の変容的な進化を掘り下げています。本レポートでは、革新的な研究、患者転帰の改善に対する需要の高まり、製薬業界の重要なセクターを管理する規制の枠組みとの相互作用について分析しています。

本レポートは、市場の現状と近年の進化について明確なイメージを確立することで、その基盤を構築しています。臨床上の利益と経済的な推進力にしっかりと焦点を当てることで、利害関係者は、絶え間ないイノベーションがいかに治療プロトコルを根本的に変えているかを理解することができます。焦点を絞ったケーススタディと比較分析を通じて、規制環境、技術的ブレークスルー、患者中心の戦略がどのように融合し、急成長と市場の多様化を促進しているかを探る。

内分泌治療薬市場の変革

内分泌治療薬の市場環境は、治療パラダイムを再定義する革命的な変化を遂げつつあります。最近の動向では、大幅な技術進歩が研究開発に拍車をかけ、患者のコンプライアンスと全体的なQOLを改善する新規治療薬の導入につながっています。データ分析と個別化医療の導入により、より的を絞ったドラッグデリバリー・システムへの道が開かれ、治療薬が個々の患者プロファイルに正確に適合するようになっています。

さらに、規制の枠組みが進化することで、患者の安全性を確保しながらイノベーションを促進する環境が整いつつあります。合理化された承認プロセスや官民の共同研究の採用により、画期的な製品の市場参入が加速しています。こうした取り組みは、医薬品開発サイクルを迅速化するだけでなく、最も効果的で安全な治療薬がより迅速に患者に届くことを保証しています。業界では、意思決定の原動力となるデジタルツールや実データを活用する動きが加速しており、より洗練されたデータ主導の戦略へと発展しています。

また、臨床研究と患者の転帰のギャップを埋める統合ケアモデルへの移行も、変革的な変化として観察されています。この戦略的アプローチは、長期の治療プロトコールとモニタリングが不可欠な慢性内分泌疾患の管理において特に重要です。高度なインスリン製剤や新しい成長ホルモン治療薬の開発など、ドラッグデリバリーにおける革新は、臨床的洞察がいかにインパクトのある治療法に結びついているかを示す例です。長期的には、こうした協調的な取り組みにより、新たな課題や機会に迅速に対応できる、より機敏で応答性の高い市場になっていくことが期待されます。

市場セグメンテーションの深掘り

内分泌薬市場のセグメンテーションを深掘りすると、戦略的意思決定に不可欠な多面的構造が明らかになります。この市場は、副腎障害、糖尿病、成長障害、骨粗鬆症、下垂体障害、甲状腺障害などの疾患が治療経路を規定する治療領域から始まり、いくつかの重要な次元にわたって調査されています。これらの各領域は、医薬品イノベーションと標的治療開発にとってユニークな課題と機会を示しています。

薬剤クラスの観点から市場を分析することで、このセグメンテーションはさらに細分化されます。カルシトニンペプチド、成長ホルモン治療薬、インスリン製剤、経口抗糖尿病薬、経口血糖降下薬、副甲状腺ホルモンとその類似薬に分類することで、生化学的アプローチと患者管理戦略の多様性が強調されます。薬剤クラス別による差別化は、臨床研究者が治療計画を最適化するのに役立つだけでなく、メーカーが製品ポートフォリオを進化する患者のニーズに合わせるのにも役立ちます。

投与様式を検討すると、吸入薬、注射薬、経口薬を包含する重層的アプローチが、市場セグメンテーションの極めて重要な要素として浮上してくる。この側面は、患者の快適性と治療レジメンの遵守を強調すると同時に、製剤技術の進歩を反映しています。好ましい投与方法は、特定の病態や最適な治療結果を得るために必要な薬物動態プロファイルによって決定されることが多いです。

患者の年齢に基づくセグメンテーションは、成人、老年、小児のグループを区別することにより、市場分析をさらに豊かにします。異なる年齢層に対するホルモン療法のニュアンスを認識することで、より正確な治療計画と臨床介入が可能になります。最後に、患者がこれらの医薬品を入手するチャネル（病院薬局からオンライン薬局、小売薬局まで）は、流通力学と市場浸透戦略に関する重要な洞察を提供します。このようなセグメンテーションの次元を全体的に把握することは、臨床と消費者の両方の需要に対応する製品とサービスを調整するために不可欠です。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 糖尿病や甲状腺機能低下症などのホルモン関連疾患の罹患率の増加
    • 治療費の負担を軽減する政府の支援政策と償還制度
  • 抑制要因
    • 内分泌治療薬の製品リコールに関する懸念
  • 機会
    • 新しい治療の研究開発におけるテクノロジー企業と製薬会社の協力の増加
    • 遠隔医療と遠隔モニタリング技術を内分泌薬物治療に統合する
  • 課題
    • 内分泌治療薬の厳格な規制環境と承認プロセス
• 市場セグメンテーション分析
  • 治療領域：副腎疾患治療の普及率の高まりとより個別化された治療
  • 薬物クラス：SGLT2阻害薬およびGLP-1受容体拮抗薬による血糖コントロールのための経口糖尿病薬の利用
  • 投与方法：患者の服薬遵守を改善するための経口投与の採用
  • 患者の年齢層：小児内分泌薬における風味豊かな製剤への嗜好の高まり
  • 流通チャネル：宅配サービスの利便性によりオンライン薬局の重要性が高まっている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 内分泌治療薬市場治療領域別

• 副腎疾患
• 糖尿病
• 成長障害
• 骨粗鬆症
• 下垂体疾患
• 甲状腺疾患

第7章 内分泌治療薬市場薬剤クラス別

• カルシトニンペプチド
• 成長ホルモン
• インスリン
• 経口抗糖尿病薬
• 経口血糖降下薬
• 副甲状腺ホルモンおよび類似体

第8章 内分泌治療薬市場投与方法別

• 吸入可能
• 注射剤
• オーラル

第9章 内分泌治療薬市場患者の年齢層別

• 成人用
• 高齢者
• 小児科

第10章 内分泌治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第11章 南北アメリカの内分泌治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の内分泌治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの内分泌治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析, 2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• Ascendis Pharma A/S
• AstraZeneca PLC
• Bayer AG
• Biocon Limited
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• CHIESI Farmaceutici S.p.A.
• Eli Lilly and Company
• Endo, Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC
• Hanmi Pharm Co., Ltd.
• Ipsen Pharma
• Johnson & Johnson Services, Inc.
• MacroGenics, Inc.
• MannKind Corporation
• Merck & Co., Inc.
• Novartis AG
• Novo Nordisk A/S
• Oramed Pharmaceuticals Inc.
• Pfizer Inc.
• Precigen, Inc.
• Sanofi S.A
• Shenzhen Microchip Biotechnology Co., Ltd.
• Sun Pharmaceutical Industries Limited
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. ENDOCRINOLOGY DRUGS MARKET MULTI-CURRENCY
• FIGURE 2. ENDOCRINOLOGY DRUGS MARKET MULTI-LANGUAGE
• FIGURE 3. ENDOCRINOLOGY DRUGS MARKET RESEARCH PROCESS
• FIGURE 4. ENDOCRINOLOGY DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. ENDOCRINOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. ENDOCRINOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ENDOCRINOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ENDOCRINOLOGY DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 50. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 53. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 75. AUSTRALIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 77. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 80. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. INDIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 82. INDIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 83. INDIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. INDIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 85. INDIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 89. INDONESIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 90. INDONESIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. JAPAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 95. JAPAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. MALAYSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 100. MALAYSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 104. PHILIPPINES ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 105. PHILIPPINES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. SINGAPORE ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 110. SINGAPORE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 114. SOUTH KOREA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 115. SOUTH KOREA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. TAIWAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 120. TAIWAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. THAILAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 125. THAILAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 129. VIETNAM ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 130. VIETNAM ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 136. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. DENMARK ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 141. DENMARK ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. EGYPT ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 146. EGYPT ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 150. FINLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 151. FINLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. FRANCE ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 156. FRANCE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. GERMANY ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 161. GERMANY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 165. ISRAEL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 166. ISRAEL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 167. ITALY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 168. ITALY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 169. ITALY ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 170. ITALY ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 171. ITALY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. NETHERLANDS ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 176. NETHERLANDS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 180. NIGERIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 181. NIGERIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 185. NORWAY ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 186. NORWAY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. POLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 188. POLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 189. POLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 190. POLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 191. POLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 192. QATAR ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 193. QATAR ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 194. QATAR ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 195. QATAR ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 196. QATAR ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 200. RUSSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 201. RUSSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 205. SAUDI ARABIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 206. SAUDI ARABIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 211. SOUTH AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 215. SPAIN ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 216. SPAIN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 220. SWEDEN ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 221. SWEDEN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 225. SWITZERLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 226. SWITZERLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 230. TURKEY ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 231. TURKEY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 235. UNITED ARAB EMIRATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 236. UNITED ARAB EMIRATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 240. UNITED KINGDOM ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 241. UNITED KINGDOM ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 242. ENDOCRINOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 243. ENDOCRINOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Endocrinology Drugs Market was valued at USD 57.11 billion in 2023 and is projected to grow to USD 61.06 billion in 2024, with a CAGR of 7.34%, reaching USD 93.80 billion by 2030.

Endocrinology drugs have emerged as both a necessity and a dynamic landscape in modern healthcare, driven by advancements in research and a deepening understanding of hormonal imbalances and metabolic disorders. In this comprehensive overview, we delve into the transformative evolution of the endocrine market while elucidating emerging trends, market segmentation specifics, and strategic regional shifts. The analysis provided here highlights the interplay between innovative research, the rising demand for improved patient outcomes, and the regulatory frameworks that govern this critical sector of the pharmaceutical industry.

This report sets the foundation by establishing a clear picture of the market's current state and its evolution over recent years. With a robust focus on clinical benefits and economic drivers, stakeholders can appreciate how continuous innovation is fundamentally altering treatment protocols. Through focused case studies and comparative analyses, the text explores how regulatory environments, technological breakthroughs, and patient-centric strategies are converging to facilitate rapid growth and market diversification.

Transformative Shifts in the Endocrinology Drugs Landscape

The market landscape for endocrinology drugs is undergoing revolutionary changes that are redefining treatment paradigms. In recent years, significant technological advancements have spurred research and development, leading to the introduction of novel therapeutic agents that improve patient compliance and overall quality of life. The infusion of data analytics and personalized medicine is paving the way for more targeted drug delivery systems, ensuring that therapies are precisely calibrated to individual patient profiles.

Furthermore, evolving regulatory frameworks have created an environment that fosters innovation while ensuring patient safety. The adoption of streamlined approval processes and collaborative research between public and private organizations serves to accelerate market entry for breakthrough products. These initiatives not only expedite the drug development cycle but also ensure that the most effective and safe therapies reach patients more rapidly. The industry is increasingly leveraging digital tools and real-world data to drive decision-making, a development that has led to more refined and data-driven strategies.

Another transformative shift observed is the move towards integrated care models that bridge the gap between clinical research and patient outcomes. This strategic approach is particularly significant in managing chronic endocrine diseases, where long-term treatment protocols and monitoring are essential. Innovations in drug delivery, such as the development of advanced insulin formulations and novel growth hormone therapies, are examples of how clinical insights are being translated into impactful treatments. Over time, these concerted efforts are expected to lead to a more agile and responsive market that is capable of adapting swiftly to new challenges and opportunities.

Deep Dive into Market Segmentation Insights

A deep dive into the segmentation of the endocrinology drugs market reveals a multifaceted structure that is crucial for strategic decision-making. The market is studied across several critical dimensions, starting with therapy areas where conditions such as adrenal disorders, diabetes, growth disorders, osteoporosis, pituitary disorders, and thyroid disorders define treatment pathways. Each of these areas presents unique challenges and opportunities for pharmaceutical innovation and targeted therapeutic development.

Analyzing the market from the perspective of drug class further refines this segmentation. The categorization into calcitonin peptides, growth hormone therapies, insulin formulations, oral antidiabetics, oral hypoglycemics, as well as parathyroid hormones and analogs, underscores the diversity in biochemical approaches and patient management strategies. The differentiation based on drug class not only aids clinical researchers in optimizing treatment plans but also supports manufacturers in aligning their product portfolios with evolving patient needs.

When examining the mode of administration, a layered approach that encompasses inhalable, injectable, and oral medications emerges as a pivotal factor in market segmentation. This dimension highlights patient comfort and adherence to treatment regimens, while also reflecting advancements in formulation technology. The preferred mode of administration is frequently dictated by the specific pathology and the requisite pharmacokinetic profile required to achieve optimal therapeutic outcomes.

Segmentation based on patient age further enriches the market analysis by distinguishing between adult, geriatric, and pediatric groups. Recognizing the nuances in hormonal therapies for different age demographics allows for more precise therapeutic planning and clinical interventions. Lastly, the channel through which patients access these medications-ranging from hospital pharmacies to online and retail pharmacies-offers critical insights into distribution dynamics and market penetration strategies. An overall view of these segmentation dimensions is essential for tailoring products and services that are responsive to both clinical and consumer demands.

Based on Therapy Area, market is studied across Adrenal Disorders, Diabetes, Growth Disorders, Osteoporosis, Pituitary Disorders, and Thyroid Disorders.

Based on Drug Class, market is studied across Calcitonin Peptides, Growth Hormone, Insulin, Oral Antidiabetics, Oral Hypoglycemics, and Parathyroid Hormones & Analogs.

Based on Mode of Administration, market is studied across Inhalable, Injectable, and Oral.

Based on Patient Age Group, market is studied across Adult, Geriatric, and Pediatric.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Regional Dynamics Shaping the Market

A comprehensive evaluation of regional dynamics underscores the importance of geographical factors in shaping the endocrinology drugs market. The Americas region has consistently showcased robust growth, driven by high rates of technological adoption and a strong emphasis on patient care innovations. Regulatory reforms in several countries within this region encourage the swift integration of novel therapies into existing healthcare systems.

In the expansive territory of Europe, the Middle East and Africa, there is a visible trend toward modernization along with an increasing adoption of evidence-based practices. This region is characterized by a complex regulatory environment that is rapidly evolving to accommodate breakthrough therapies. Companies operating within these regions are increasingly aligning their strategies to meet the stringent requirements of diverse markets, making significant strides in both research collaborations and distribution innovations.

The Asia-Pacific region is witnessing accelerated growth attributed to a large patient base and rising healthcare investments. The blend of urbanization and improved healthcare infrastructure in emerging economies within this territory is fueling demand for advanced endocrinology drugs. As the market continues to mature, enhanced regulatory frameworks and increased healthcare awareness are expected to further drive expansion throughout the region. These regional analyses collectively provide a broad yet detailed picture of how geographical considerations are integral to market planning and strategic positioning in the current global landscape.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Steering Growth and Innovation

The role of leading companies in driving market innovation and expanding therapeutic options cannot be overstated. The competitive landscape features renowned multinational corporations and agile biopharmaceutical innovators who are continually pushing the boundaries of research and development. Companies such as Abbott Laboratories and AbbVie Inc. stand out as pioneers in leveraging cutting-edge technology and precision medicine in their product development pipelines. Additionally, firms like Ascendis Pharma A/S and AstraZeneca PLC are well-recognized for their contributions to endocrinology through both novel formulations and sustained clinical trials.

Other major players including Bayer AG and Biocon Limited are also making significant inroads in this space, with a strong emphasis on quality improvements and therapeutic efficacy. Firms such as Boehringer Ingelheim International GmbH and Bristol-Myers Squibb Company have built reputations for innovative drug development processes that have transformed patient care standards. CHIESI Farmaceutici S.p.A. alongside Eli Lilly and Company further exemplify the sector's commitment to research excellence and regulatory adherence.

Moreover, companies like Endo, Inc. and F. Hoffmann-La Roche Ltd. continue to set benchmarks in clinical research and market penetration. The activities of influential industry leaders such as GlaxoSmithKline PLC and Hanmi Pharm Co., Ltd. are reflective of the broader ethos driving the market toward more personalized medication regimes. Ipsen Pharma and Johnson & Johnson Services, Inc. have also carved out significant market segments through strategic acquisitions and innovation. Emerging firms, including MacroGenics, Inc. and MannKind Corporation, bring fresh perspectives that contribute to the dynamic evolution of the industry.

Industry giants such as Merck & Co., Inc., Novartis AG, and Novo Nordisk A/S play central roles in facilitating the transition to next-generation therapies with their advanced research capabilities. The innovative approaches of Oramed Pharmaceuticals Inc. and Pfizer Inc. in developing novel drug classes provide valuable insights into the shifting market dynamics. This landscape is further enriched by the pioneering work of companies like Precigen, Inc. and Sanofi S.A, which continuously refine their product portfolios to meet emerging patient needs. In addition, organizations such as Shenzhen Microchip Biotechnology Co., Ltd., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd. contribute immensely to the widespread dissemination and accessibility of endocrinology drugs. Collectively, these companies are at the forefront of fostering innovations that are set to redefine treatment paradigms across global markets.

The report delves into recent significant developments in the Endocrinology Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Ascendis Pharma A/S, AstraZeneca PLC, Bayer AG, Biocon Limited, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, CHIESI Farmaceutici S.p.A., Eli Lilly and Company, Endo, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Hanmi Pharm Co., Ltd., Ipsen Pharma, Johnson & Johnson Services, Inc., MacroGenics, Inc., MannKind Corporation, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., Precigen, Inc., Sanofi S.A, Shenzhen Microchip Biotechnology Co., Ltd., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.. Actionable Recommendations for Industry Leaders

For industry leaders, the insights provided in this extensive review offer a significant opportunity to refine strategic approaches and benchmark against evolving market trends. It is imperative for companies to cultivate robust research and development pipelines while embracing innovative technologies that enable more accurate and efficient drug delivery solutions. One actionable recommendation is to prioritize investments in personalized medicine and digital health solutions that facilitate real-time data analytics, thereby enhancing patient monitoring and treatment compliance.

Furthermore, engaging in cross-sector collaborations and public-private partnerships can be instrumental in catalyzing development processes and reducing time-to-market for breakthrough therapies. Leveraging advanced analytics and artificial intelligence to optimize clinical trial designs and patient recruitment strategies stands as a critical pathway to enhancing research outcomes. Industry leaders should also consider diversifying distribution strategies by aligning with digital platforms, as well as optimizing traditional retail and hospital-based channels, to maximize product accessibility and market penetration.

Another strategic recommendation involves tailoring product portfolios to meet the distinct needs of various market segments. By infusing research with insights about therapy areas, drug classes, patient demographics, and preferred modes of administration, companies can craft targeted approaches that yield high therapeutic efficacy and improved patient outcomes. Leader organizations are encouraged to foster an environment of continuous innovation, ensuring that their offerings evolve in tandem with shifting regulatory landscapes and evolving consumer expectations. By integrating these strategic imperatives, companies can not only secure a competitive advantage but also position themselves as pioneers in the rapidly evolving endocrinology drugs market.

Conclusion: Summarizing Key Insights and Future Outlook

The analysis presented in this summary brings into focus the myriad factors that are shaping the future of the endocrinology drugs market. In summary, the industry is witnessing a confluence of technological innovations, regulatory reforms, and patient-centric strategies that synergistically drive market growth. A systematic approach to understanding market segmentation-whether by therapy area, drug class, mode of administration, patient age, or distribution channel-reveals targeted opportunities that companies can harness to refine their product offerings and market strategies.

Regional insights further underscore the importance of adopting a localized strategy that respects the diverse market dynamics of the Americas, Europe, the Middle East and Africa, and the Asia-Pacific. These geographically tailored strategies are imperative for companies aiming to capitalize on region-specific trends, regulatory environments, and patient demographics. Moreover, the role played by leading companies in the evolution of this market cannot be underestimated. Their pioneering work in research and innovation sets a high benchmark for the industry, pushing the boundaries continuously in pursuit of improved patient outcomes.

As the market continues to evolve, the integration of advanced digital tools, strategic investments in research, and robust partnerships emerges as the way forward. This confluence of factors not only creates a fertile ground for innovation but also lays the foundation for a more agile, responsive, and patient-focused healthcare system. In conclusion, the comprehensive insights shared in this summary serve as a guiding framework for stakeholders looking to navigate and succeed in this dynamic industry.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of hormone-related disorders such as diabetes and thyroid imbalances
    • 5.1.1.2. Supportive government policies and reimbursement schemes enhancing the affordability of treatments
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with product recall of endocrinology drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising collaborations between technology firms and drug manufacturers for R & D of new treatment
    • 5.1.3.2. Integrating telemedicine and remote monitoring technologies with endocrinology drug treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory environments and approval processes for endocrinology drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Therapy Area: Growing prevalence of adrenal disorders treatment for more personalized treatment
  • 5.2.2. Drug Class: Utilization of oral antidiabetics for glycemic control due to SGLT2 inhibitors and GLP-1 receptor
  • 5.2.3. Mode of Administration: Adoption of oral endocrinology drugs for improving patient adherence
  • 5.2.4. Patient Age Group: Rising preference for flavorful formulations in pediatric endocrinology medications
  • 5.2.5. Distribution Channel: Increasing significance of online pharmacies due to ease of home delivery services
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Endocrinology Drugs Market, by Therapy Area

• 6.1. Introduction
• 6.2. Adrenal Disorders
• 6.3. Diabetes
• 6.4. Growth Disorders
• 6.5. Osteoporosis
• 6.6. Pituitary Disorders
• 6.7. Thyroid Disorders

7. Endocrinology Drugs Market, by Drug Class

• 7.1. Introduction
• 7.2. Calcitonin Peptides
• 7.3. Growth Hormone
• 7.4. Insulin
• 7.5. Oral Antidiabetics
• 7.6. Oral Hypoglycemics
• 7.7. Parathyroid Hormones & Analogs

8. Endocrinology Drugs Market, by Mode of Administration

• 8.1. Introduction
• 8.2. Inhalable
• 8.3. Injectable
• 8.4. Oral

9. Endocrinology Drugs Market, by Patient Age Group

• 9.1. Introduction
• 9.2. Adult
• 9.3. Geriatric
• 9.4. Pediatric

10. Endocrinology Drugs Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Americas Endocrinology Drugs Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Endocrinology Drugs Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Endocrinology Drugs Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. AdipoPharma secures funding for phase 1 trials of type 2 diabetes insulin resistance drug
  • 14.3.2. Eton Pharmaceuticals acquires Increlex from Ipsen for enhancing its pediatric endocrinology portfolio
  • 14.3.3. MITEM PHARMA's strategic acquisition of DESFERAL enhances drug accessibility for serious hematological conditions
  • 14.3.4. FDA approval of Ascendis Pharma's Yorvipath signals new hope for hypoparathyroidism treatment
  • 14.3.5. AstraZeneca's strategic acquisition of Amolyt Pharma enhances rare disease pipeline with groundbreaking endocrinology treatment
  • 14.3.6. Valendo Health secures USD 4 million in seed funding and partnered with Cecelia Health and Advanced Metabolic Care
  • 14.3.7. Henlius and Sermonix announce strategic collaboration and exclusive license agreements for novel endocrine therapy lasofoxifene
  • 14.3.8. Specialised Therapeutics expands endocrinology portfolio through exclusive agreement with Ascendis Pharma for distribution in Oceania and Southeast Asia
  • 14.3.9. Menarini Group and Insilico Medicine enter global exclusive license agreement for novel KAT6 inhibitor
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. Sanofi S.A.
  • 14.4.2. Novo Nordisk A/S
  • 14.4.3. Eli Lilly and Company
  • 14.4.4. AstraZeneca PLC

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Ascendis Pharma A/S
• 4. AstraZeneca PLC
• 5. Bayer AG
• 6. Biocon Limited
• 7. Boehringer Ingelheim International GmbH
• 8. Bristol-Myers Squibb Company
• 9. CHIESI Farmaceutici S.p.A.
• 10. Eli Lilly and Company
• 11. Endo, Inc.
• 12. F. Hoffmann-La Roche Ltd.
• 13. GlaxoSmithKline PLC
• 14. Hanmi Pharm Co., Ltd.
• 15. Ipsen Pharma
• 16. Johnson & Johnson Services, Inc.
• 17. MacroGenics, Inc.
• 18. MannKind Corporation
• 19. Merck & Co., Inc.
• 20. Novartis AG
• 21. Novo Nordisk A/S
• 22. Oramed Pharmaceuticals Inc.
• 23. Pfizer Inc.
• 24. Precigen, Inc.
• 25. Sanofi S.A
• 26. Shenzhen Microchip Biotechnology Co., Ltd.
• 27. Sun Pharmaceutical Industries Limited
• 28. Takeda Pharmaceutical Company Limited
• 29. Teva Pharmaceutical Industries Ltd.